Table 1.
Sample characteristics
| Patient/age | Baseline
|
Follow-up
|
||||
|---|---|---|---|---|---|---|
| Viral load* | CD4† | Prior RTI | ANS activity‡ | Duration§ | HAART | |
| 014/54 | 276,316 | 297 | AZT | −1.61 | 3.0 | SAQ, d4T, 3TC |
| 043/37 | 4,948 | 697 | −1.27 | 10.9 | NEL, d4T, 3TC | |
| 027/29 | 16,561 | 446 | AZT, 3TC | −0.88 | 10.5 | IND, NEV, d4T |
| 060/44 | 65,567 | 259 | AZT, 3TC | −0.87 | 9.1 | RIT, SAQ, d4T, ddI |
| 015/42 | 101,553 | 396 | −0.77 | 3.0 | IND, AZT, 3TC | |
| 024/42 | 13,115 | 316 | −0.18 | 11.6 | NEL, d4T, 3TC | |
| 039/35 | 1,646 | 640 | AZT, 3TC | 0.19 | 4.0 | IND, AZT, 3TC, ddC |
| 042/44 | 40,331 | 328 | AZT, ddI | 0.31 | 4.5 | SAQ, d4T, 3TC |
| 037/34 | 422,321 | 699 | 0.75 | 4.8 | SAQ, AZT, 3TC | |
| 032/43 | 16,367 | 571 | AZT, ddI | 0.93 | 3.5 | IND, d4T, 3TC |
| 058/25 | 46,717 | 449 | 0.96 | 3.0 | SAQ, d4T, 3TC | |
| 016/30 | 312,383 | 914 | AZT | 0.99 | 3.0 | SAQ, AZT, ddC |
| 062/36 | 102,632 | 650 | 1.46 | 10.9 | RIT, INV, AZT, 3TC | |
*
Mean plasma HIV-1 RNA copies/mm3 during 2-week baseline. IND, indinavir; NEL, nelfinavir; RIT, ritonavir; SAQ, saquinavir; AZT, zidovudine; ddI, didanosine; 3TC, lamivudine; d4T, stavudine; ddC, zalcitabine; NEV, nevirapine; DEL, delavirdine.
†
Mean peripheral blood CD3+/CD4+ lymphocytes/mm3 during 2-week baseline.
‡
ANS activity level, averaging across indicators and measurement conditions, expressed as SD units relative to mean value (e.g, −1.0 = 1 SD below mean value).
§
Duration of HAART at follow-up (months).